Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,999,080
  • Shares Outstanding, K 2,623,764
  • Annual Sales, $ 22,090 M
  • Annual Income, $ 2,155 M
  • 60-Month Beta 0.48
  • Price/Sales 5.56
  • Price/Cash Flow 14.57
  • Price/Book 8.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.46
  • Number of Estimates 1
  • High Estimate 0.46
  • Low Estimate 0.46
  • Prior Year 0.79
  • Growth Rate Est. (year over year) -41.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.63 +7.45%
on 10/16/19
49.22 -4.74%
on 11/01/19
+3.30 (+7.57%)
since 10/11/19
3-Month
42.19 +11.12%
on 09/10/19
49.22 -4.74%
on 11/01/19
+2.11 (+4.71%)
since 08/09/19
52-Week
35.30 +32.80%
on 01/28/19
49.22 -4.74%
on 11/01/19
+5.91 (+14.43%)
since 11/09/18

Most Recent Stories

More News
Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

PFE : 36.93 (-0.32%)
MRK : 83.28 (-0.37%)
BMY : 58.15 (+0.22%)
AZN : 46.88 (-0.80%)
Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators

--Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa

AZN : 46.88 (-0.80%)
New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease

AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA(R) (dapagliflozin) for the treatment of heart failure (HF). The data showed that...

AZN : 46.88 (-0.80%)
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

BMY : 58.15 (+0.22%)
SNY : 45.86 (unch)
JNJ : 131.98 (-0.77%)
AGN : 181.58 (+0.17%)
AZN : 46.88 (-0.80%)
NVS : 88.63 (+0.29%)
NVO : 57.29 (-1.00%)
Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials

--ROCKIES demonstrated a mean increase of 0.77g/dL averaged over weeks 28 to 52, compared to 0.68g/dL with epoetin alfa

AZN : 46.88 (-0.80%)
CALQUENCE(R) Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting

AstraZeneca will present the first data from the Phase III ELEVATE-TN trial assessing CALQUENCE(R) (acalabrutinib), a next-generation selective Bruton's tyrosine kinase (BTK) inhibitor, in patients with...

AZN : 46.88 (-0.80%)
New Hope in the Battle Against Ovarian Cancer

Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target...

RHHBY : 37.5550 (+0.44%)
GSK : 44.26 (-0.36%)
AZN : 46.88 (-0.80%)
BMY : 58.15 (+0.22%)
POAI : 3.90 (-9.30%)
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.

AGN : 181.58 (+0.17%)
AZN : 46.88 (-0.80%)
IRWD : 11.11 (+0.82%)
CYCN : 2.06 (+8.42%)
BMY or AZN: Which Is the Better Value Stock Right Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY : 58.15 (+0.22%)
AZN : 46.88 (-0.80%)
Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

AZN : 46.88 (-0.80%)
AGN : 181.58 (+0.17%)
MNK : 2.86 (-8.04%)
MYL : 17.24 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 47.34
1st Resistance Point 47.11
Last Price 46.88
1st Support Level 46.52
2nd Support Level 46.16

See More

52-Week High 49.22
Last Price 46.88
Fibonacci 61.8% 43.90
Fibonacci 50% 42.26
Fibonacci 38.2% 40.62
52-Week Low 35.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar